Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee February 2005
1. ALAN HAMPSONADULTA/NEW CALEDONIA/20/99-LIKE (H1N1) WHO, AUSTRALIAELDERA/WYOMING/3/2003 (H3N2) B/BRISBANE/32/ JOHN WOOD, PH.DADULTA/NEW CALEDONIA/20/99 (H1N1) NIBSC, ENGLANDELDERA/WYOMING/3/2003 (H3N2) B/JIANGSU/10/ TAKATO ODIGARI, PH.D. ADULTA/NEW CALEDONIA/20/99-LIKE (H1N1) WHO, JAPANELDERA/WYOMING/3/2003 (H3N2) B/SHANGHAI/361/2003 Serum Panels for Serologies
4. STEFAN GRAVENSTEIN, M.D.ADULTA/NEW CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA ELDERA/WYOMING/3/2003 (H3N2) MEDICAL SCHOOLCHILDB/JIANGSU/10/ WILLIAM KOCH, M.D.CHILDA/NEW CALEDONIA/20/99 (H1N1) VIRGINIA COMMONWEALTHA/WYOMING/3/2003 UNIVERSITYB/JIANGSU/10/2003
ANTIGENS FOR SEROLOGIES (H1) VACCINE STRAIN A/NEW CALEDONIA/20/99 (H1N1) REPRESENTATIVE CURRENT STRAINS A/BANGKOK/1544/2004 (H1N1) A/FLORIDA/4/2004 (H1N1) A/NETHERLANDS/128/2004 (H1N1) A/NEW CALEDONIA/9/2004 (H1N1) A/OKINAWA/42/2004 (H1N1) A/SAITAMA/78/2004 (H1N1) A/SINGAPORE/14/2004 (H1N1)
HI ANTIBODY RESPONSES TO THE H1 COMPONENT INFLUENZA VACCINE ADULT POPULATION (CBER)
HI ANTIBODY RESPONSES TO THE H1 COMPONENT INFLUENZA VACCINE ELDERLY POPULATION (NIBSC)
HI ANTIBODY RESPONSES TO THE H1 COMPONENT INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)
A/NEW CALEDONIA/20/99 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION
ANTIGENS FOR SEROLOGIES (H3) VACCINE STRAIN A/WYOMING/3/2003 REPRESENTATIVE CURRENT STRAINS A/BANGKOK/1563/2004 A/CALIFORNIA/7/2004 A/OSAKA/36/2004 A/OSLO/8/2004 A/SHANTOU/1219/2004 A/SINGAPORE/36/2004 A/SINGAPORE/37/2004 A/TENNESSEE/6/2004 A/TOKYO/1035/2004 A/VICTORIA/523/2004
HI ANTIBODY RESPONSES TO THE H3 COMPONENT INFLUENZA VACCINE ADULT POPULATION ( CDC )
HI ANTIBODY RESPONSES TO THE H3 COMPONENT INFLUENZA VACCINE ELDERLY POPULATION (NIBSC)
HI ANTIBODY RESPONSES TO THE H3 COMPONENT INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)
A/WYOMING/3/2003 VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION
ANTIGENS FOR SEROLOGIES (B) VACCINE STRAIN B/BRISBANE/32/2002* B/JIANGSU/10/2003+ REPRESENTATIVE CURRENT STRAINS B/HAWAII/13/2004* B/PHITSANULOK/2053/2004* B/COLORADO/4/2004+ B/FLORIDA/7/2004+ B/FUJIAN/430/2004+ * = HONG KONG/330-LIKE B/LISBON/1/ = SHANGHAI/361-LIKE B/SHIZUOKA/2/2004+ B/SHIZUOKA/58/2004+ B/VICTORIA/501/2004+
HI ANTIBODY RESPONSES TO THE B COMPONENT INFLUENZA VACCINE ADULT POPULATION (CDC)
HI ANTIBODY RESPONSES TO THE B COMPONENT INFLUENZA VACCINE ELDERLY POPULATION (AUS)
HI ANTIBODY RESPONSES TO THE B COMPONENT INFLUENZA VACCINE PEDIATRIC POPULATION (CDC AND CBER)
B/SHANGHAI/361/2002-LIKE VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION
Influenza Vaccine Responses Summary Studies with sera collected after immunization with current vaccines show that: Representative influenza A (H1N1) viruses are well-inhibited A/California/7/2004 (H3N2)-like viruses are poorly inhibited compared to the vaccine strain B/Shanghai/361/2002-like viruses are reasonably well-inhibited but B/Hong Kong/330/2001-like viruses are less well inhibited than the vaccine strains